BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36901808)

  • 1. In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31.
    Sun W; Wong ILK; Law HK; Su X; Chan TCF; Sun G; Yang X; Wang X; Chan TH; Wan S; Chow LMC
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
    Li H; Krstin S; Wink M
    Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers.
    Wong ILK; Wang XK; Liu Z; Sun W; Li FX; Wang BC; Li P; Wan SB; Chow LMC
    Eur J Med Chem; 2021 Dec; 226():113795. PubMed ID: 34597896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo.
    Yan CS; Wong IL; Chan KF; Kan JW; Chong TC; Law MC; Zhao Y; Chan SW; Chan TH; Chow LM
    Mol Pharm; 2015 Oct; 12(10):3507-17. PubMed ID: 26291333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
    Abraham I; Jain S; Wu CP; Khanfar MA; Kuang Y; Dai CL; Shi Z; Chen X; Fu L; Ambudkar SV; El Sayed K; Chen ZS
    Biochem Pharmacol; 2010 Nov; 80(10):1497-506. PubMed ID: 20696137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of P-glycoprotein-mediated multidrug resistance by novel curcumin analogues in paclitaxel-resistant human breast cancer cells.
    Gao L; Zhao P; Li Y; Yang D; Hu P; Li L; Cheng Y; Yao H
    Biochem Cell Biol; 2020 Aug; 98(4):484-491. PubMed ID: 31967866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel.
    Kan JWY; Yan CSW; Wong ILK; Su X; Liu Z; Chan TH; Chow LMC
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
    Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
    Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
    Li YS; Yang X; Zhao DS; Cai Y; Huang Z; Wu R; Wang SJ; Liu GJ; Wang J; Bao XZ; Ye XY; Wei B; Cui ZN; Wang H
    Eur J Med Chem; 2021 Apr; 216():113336. PubMed ID: 33725657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
    Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
    Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency.
    Lin R; Zhang L; Ye B; Wang Y; Li YD; Jason H; Liu W; Hu P; Chen J; Chen ZS; Chen Z
    Cancer Lett; 2023 Jun; 563():216181. PubMed ID: 37086953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.